Athanasios Vasilopoulos

机构：AbbVie (United States)

发表论文 47 篇 · 总被引 583 次 · h-index 9

代表论文

• Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib (2025 · Annals of Oncology · 被引 41)
• First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. (2024 · Journal of Clinical Oncology · 被引 21)
• Heterogeneous Embedded Neural Processing Units Utilizing PCM-Based Analog In-Memory Computing (2024 · 被引 15)
• 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study (2024 · Annals of Oncology · 被引 12)
• In-Memory Compute Chips with Carbon-based Projected Phase-Change Memory Devices (2023 · 被引 9)
• 515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates (2023 · Annals of Oncology · 被引 9)